Stability of Cardiac Biomarkers Tested in Different Samples
By LabMedica International staff writers Posted on 09 Jan 2018 |

Image: The ARCHITECT i2000SR immunoassay analyzer (Photo courtesy of Abbott Diagnostics).
Blood-based biomarkers, such as cardiac troponin (cTn) and galectin-3, are widely used in clinical trials and/or in clinical routines as an aid for the diagnosis and risk stratification of patients with heart disease.
When blood samples are used for biomarker measurements in clinical routine analyses, efforts should be made to process these samples immediately after blood collection to provide immediate results for timely diagnosis and therapy and to avoid any pre-analytical errors.
Doctors at Konventhospital Barmherzige Brueder Linz, (Linz, Austria) tested the hypothesis that the analytes hs-cTnI, hs-cTnT and galectin-3 are stable in vitro at a storage temperature of −80 °C for at least one year, and they used blood samples from clinical routine analyses. The analyte concentrations of 30 patients were measured in heparin-treated plasma, EDTA-treated plasma and serum samples after the following storage conditions: 1) samples used immediately after blood collection for baseline measurements; 2) samples stored for six months at −80 °C after one freeze-thaw cycle; 3) samples stored for one year at −80 °C after two freeze-thaw cycles; and 4) samples stored for one year at −80 °C after one freeze-thaw cycle.
Circulating concentrations of high-sensitivity cardiac troponin I (hs-cTnI) were measured with the STAT High Sensitive Troponin-I assay on the Abbott ARCHITECT i2000SR analyzer. The team measured hs-cTnT concentrations with the Troponin T hs assay on the Roche cobas e 411. The scientists also measured galectin-3 with the Abbott Diagnostics routine Galectin-3 assay on an ARCHITECT i2000SR analyzer.
The investigators reported that baseline hs-cTnI, hs-cTnT and galectin-3 concentrations ranged from 2.3 to 5,436 ng/L, from 5.3 to 850 ng/L, and from 8.3 to 79.3 ng/mL, respectively. After applying the default criterion for analyte stability, the three analytes were stable for at least one year even after two freeze-thaw cycles for each sample type. They observed the following variation in analyte concentrations after storage relative to the baseline values: the interquartile range (IQR) of cardiac troponin results extended from approx. 80% to 115%, and the IQR of galectin-3 results extended from approx. 90% to 110%.
The authors concluded that hs-cTnI, hs-cTnT and galectin-3 were stable under the reported storage conditions irrespective of the sample type used. However, they observed a considerable variation in analyte concentrations after sample storage, which might affect the diagnostic/prognostic value of these analytes in individual patients using frozen blood samples. The study was published in the January 2018 issue of the journal Clinica Chimica Acta.
Related Links:
Konventhospital Barmherzige Brueder
When blood samples are used for biomarker measurements in clinical routine analyses, efforts should be made to process these samples immediately after blood collection to provide immediate results for timely diagnosis and therapy and to avoid any pre-analytical errors.
Doctors at Konventhospital Barmherzige Brueder Linz, (Linz, Austria) tested the hypothesis that the analytes hs-cTnI, hs-cTnT and galectin-3 are stable in vitro at a storage temperature of −80 °C for at least one year, and they used blood samples from clinical routine analyses. The analyte concentrations of 30 patients were measured in heparin-treated plasma, EDTA-treated plasma and serum samples after the following storage conditions: 1) samples used immediately after blood collection for baseline measurements; 2) samples stored for six months at −80 °C after one freeze-thaw cycle; 3) samples stored for one year at −80 °C after two freeze-thaw cycles; and 4) samples stored for one year at −80 °C after one freeze-thaw cycle.
Circulating concentrations of high-sensitivity cardiac troponin I (hs-cTnI) were measured with the STAT High Sensitive Troponin-I assay on the Abbott ARCHITECT i2000SR analyzer. The team measured hs-cTnT concentrations with the Troponin T hs assay on the Roche cobas e 411. The scientists also measured galectin-3 with the Abbott Diagnostics routine Galectin-3 assay on an ARCHITECT i2000SR analyzer.
The investigators reported that baseline hs-cTnI, hs-cTnT and galectin-3 concentrations ranged from 2.3 to 5,436 ng/L, from 5.3 to 850 ng/L, and from 8.3 to 79.3 ng/mL, respectively. After applying the default criterion for analyte stability, the three analytes were stable for at least one year even after two freeze-thaw cycles for each sample type. They observed the following variation in analyte concentrations after storage relative to the baseline values: the interquartile range (IQR) of cardiac troponin results extended from approx. 80% to 115%, and the IQR of galectin-3 results extended from approx. 90% to 110%.
The authors concluded that hs-cTnI, hs-cTnT and galectin-3 were stable under the reported storage conditions irrespective of the sample type used. However, they observed a considerable variation in analyte concentrations after sample storage, which might affect the diagnostic/prognostic value of these analytes in individual patients using frozen blood samples. The study was published in the January 2018 issue of the journal Clinica Chimica Acta.
Related Links:
Konventhospital Barmherzige Brueder
Latest Clinical Chem. News
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
Channels
Molecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more